Onsdag 5 Februari | 09:51:16 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-11-27 N/A Årsstämma
2025-10-30 07:30 Bokslutskommuniké 2025
2025-07-24 08:30 Kvartalsrapport 2025-Q3
2025-04-25 08:30 Kvartalsrapport 2025-Q2
2025-01-30 - Kvartalsrapport 2025-Q1
2024-11-29 - X-dag ordinarie utdelning NXTCL 0.00 SEK
2024-11-28 - Årsstämma
2024-10-24 - Bokslutskommuniké 2024
2024-07-25 - Kvartalsrapport 2024-Q3
2024-05-27 - Extra Bolagsstämma 2024
2024-04-25 - Kvartalsrapport 2024-Q2
2024-01-25 - Kvartalsrapport 2024-Q1
2023-12-01 - X-dag ordinarie utdelning NXTCL 0.00 SEK
2023-11-30 - Årsstämma
2023-10-26 - Bokslutskommuniké 2023
2023-07-27 - Kvartalsrapport 2023-Q3
2023-04-27 - Kvartalsrapport 2023-Q2
2023-01-26 - Kvartalsrapport 2023-Q1
2022-11-25 - X-dag ordinarie utdelning NXTCL 0.00 SEK
2022-11-24 - Årsstämma
2022-10-27 - Bokslutskommuniké 2022
2022-07-28 - Kvartalsrapport 2022-Q3
2022-04-28 - Kvartalsrapport 2022-Q2
2022-01-27 - Kvartalsrapport 2022-Q1
2021-11-25 - X-dag ordinarie utdelning NXTCL 0.00 SEK
2021-11-24 - Årsstämma
2021-10-29 - Bokslutskommuniké 2021
2021-07-30 - Kvartalsrapport 2021-Q3
2021-04-29 - Kvartalsrapport 2021-Q2
2021-01-29 - Kvartalsrapport 2021-Q1
2020-11-25 - X-dag ordinarie utdelning NXTCL 0.00 SEK
2020-11-24 - Årsstämma
2020-10-30 - Bokslutskommuniké 2020
2020-07-31 - Kvartalsrapport 2020-Q3
2020-06-03 - Extra Bolagsstämma 2020
2020-04-30 - Kvartalsrapport 2020-Q2
2020-01-31 - Kvartalsrapport 2020-Q1
2019-12-06 - X-dag ordinarie utdelning NXTCL 0.00 SEK
2019-12-05 - Årsstämma
2019-10-31 - Bokslutskommuniké 2019
2019-07-31 - Kvartalsrapport 2019-Q3
2019-04-30 - Kvartalsrapport 2019-Q2
2019-01-31 - Kvartalsrapport 2019-Q1
2018-12-05 - Årsstämma
2018-11-01 - X-dag ordinarie utdelning NXTCL 0.00 SEK
2018-10-31 - Bokslutskommuniké 2017
2018-07-31 - Kvartalsrapport 2017-Q3
2017-12-06 - X-dag ordinarie utdelning NXTCL 0.00 SEK
2017-12-05 - Årsstämma

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
NextCell Pharma är verksamt inom hälsovårdssektorn. Idag sker utveckling av stamcellsprodukter som huvudsakligen används vid behandling av autoimmun diabetes och vid njurtransplantation. En stor del av arbetet består av stamcellsforskning där bolaget utvecklar läkemedelskandidater som skall underlätta och öka acceptansen vid organtransplantation. Utöver innehar bolaget en stamcellsbank. Bolaget etablerades 2014 och har sitt huvudkontor i Huddinge.
2024-11-04 08:30:00

NextCell Pharma AB* proudly announces its participation in BIO-Europe 2024, one of Europe's most significant partnering conferences in biotechnology and pharmaceutical development. The event will be held at Stockholmsmässan from November 4-6, and is expected to gather over 5,000 leading professionals from around the world.

During BIO-Europe, NextCell will be an active part of the Swedish pavilion organized by Business Sweden, providing a unique opportunity to showcase NextCell's advancements and contributions in cell therapy and precision medicine. The company also looks forward to participating in several partnering meetings during the conference, facilitating strategic discussions and collaboration opportunities with international stakeholders.

As part of the Swedish business initiative at BIO-Europe, NextCell is honored to welcome Sweden's Minister for Energy, Business and Industry and Deputy Prime Minister, Ebba Busch, to their booth in the Swedish pavilion. The minister's visit is an important recognition for NextCell and other Swedish companies leading the way in biotechnology. Busch's presence underscores the government's commitment to strengthening the international competitiveness of Swedish biotech companies and promoting innovation for a sustainable future.

"Participating in BIO-Europe and being part of the Swedish pavilion is a strategically important opportunity for NextCell. We look forward to fruitful discussions and expanding our global network," says Mathias Svahn, CEO of NextCell Pharma AB. "It is also an honor to welcome Ebba Busch, which highlights the significance of the biotech sector for Sweden and the future of healthcare."

BIO-Europe 2024 is expected to be a highly engaging event with a focus on innovation, partnerships, and growth within biotechnology. NextCell Pharma AB looks forward to representing Swedish biotech and continuing efforts for better global health through groundbreaking cell therapies and treatments.

* NextCell Pharma AB, "NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL